New Clinical Trials Of Monoclonal Antibodies Have Grown 115 Percent In 10 Years

New clinical trials of monoclonal antibodies (mAb), have grown 115 percent globally over the ten year period from 2007–2016 according to GlobalData, a leading data and analytics company. The most prominent increase, 26 percent, occurred in 2015.

The company tracks clinical trials activity across the world and has identified 5,273 industry mAb clinical trials with a start date between January 1, 2007, and December 31, 2016.

A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 31 percent and 46 percent across the period.

A spokesperson from the GlobalData Pharma analyst team commented: “The share of Phase I trials started at 18 percent in 2007 and increased to 27 percent by 2016. Phase III trials’ contribution remained flat at an average of 24 percent across the 10-year period, whereas Phase IV trials decreased in share from 13 to 12 percent in the first and last years, respectively.”